Brought to you by 
BI to acquire remaining shares of OTC drug maker SSP
18 Feb 2010
Executive Summary
Boehringer Ingelheim plans to acquire the 39.8% of top public Japanese OTC drug player SSP that it doesn't already own for Y33bn ($368.6mm). BI would pay Y710 per share, a 36% premium.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI to acquire remaining shares of OTC drug maker SSP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice